徐玲,赵威,崔鸣,高炜

• 1:北京大学第三医院心内科卫生部心血管分子生物学与调节肽重点实验室分子心血管学教育部重点实验室心血管受体研究北京市重点实验室

摘要(Abstract)：

<正>当前,冠状动脉粥样硬化性心脏病仍是造成国人致死和致残的主要病因之一。抗血小板治疗是冠心病治疗的重要组成部分,氯吡格雷与阿司匹林的双联用药已成为急性冠状动脉综合征(acute coronary syndrome,ACS)/经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)患者的标准治疗方案,但仍有大量血栓事件发生。有研究提示,人体对

关键词(KeyWords)： CYP2C19基因多态性;新型抗血小板治疗;冠心病;经皮冠状动脉介入治疗

Abstract:

Keywords:

基金项目(Foundation): 中国心血管医师研究基金(2013年)

作者(Author): 徐玲,赵威,崔鸣,高炜

参考文献(References)：

• [1]Norgard NB,Di Nicolantonio JJ.P2Y12antagonists in non-STsegment elevation acute coronary syndromes:latest evidence and optimal use.Ther Adv Chronic Dis,2015,6(4):204-218.
• [2]Mao L,Jian C,Changzhi L,et al.Cytochrome CYP2C19polymorphism and risk of adverse clinical events in clopidogreltreated patients:a meta-analysis based on 23,035 subjects.Arch Cardiovasc Dis,2013,106(10):517-527.
• [3]Scott SA,Sangkuhl K,Shuldiner AR,et al.Pharm GKB summary:very important pharmacogene information for cytochrome P450,family 2,subfamily C,polypeptide 19.Pharmacogenet Genomics,2012,22(2):159-165.
• [4]Scott SA,Sangkuhl K,Stein CM,et al.Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy:2013 update.Clin Pharmacol Ther,2013,94(3):317-323.
• [5]Hulot JS,Bura A,Villard E,et al.Cytochrome P450 2C19 lossof-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.Blood,2006,108(7):2244-2247.
• [6]Sabatine MS,Mega JL.Pharmacogenomics of antiplatelet drugs.Hematology Am Soc Hematol Educ Program,2014,1:343-347.
• [7]Jang JS,Cho KI,Jin HY,et al.Meta-analysis of cytochrome P4502C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel.Am J Cardiol,2012,110(4):502-508.
• [8]Zabalza M,Subirana I,Sala J,et al.Meta-analyses of theassociation between cytochrome CYP2C19 loss-and gain-offunction polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.Heart,2012,98(2):100-108.
• [9]Amsterdam EA,Wenger NK,Brindis RG,et al.2014 AHA/ACC guideline for the management of patients with non-STelevation acute coronary syndromes:executive summary:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.Circulation,2014,130(25):2354-2394.
• [10]Roffi M,Patrono C,Collet JP,et al.2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.Kardiol Pol,2015,73(12):1207-1294.
• [11]Bergmeijer TO,Janssen PW,Schipper JC,et al.CYP2C19genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI(POPular)Genetics study.Am Heart J,2014,168(1):17-22.
• [12]Mega JL,Close SL,Wiviott SD,et al.Cytochrome P450 genetic polymorphisms and the response to prasugrel:relationship to pharmacokinetic,pharmacodynamics,and clinical outcomes.Circulation,2009,119(19):2553-2560.
• [13]Jason DR,George AW,Michel RL,et al.Point-of-care genetic testing for personalisation of antiplatelet treatment(RAPID GENE):a prospective,randomised,proof-of-concept trial.Lancet,2012,379(9827):1705-1711.
• [14]Sorich MJ,Vitry A,Ward MB,et al.Prasugrel vs.clopidogrel for cytochrome P450 2C19-genotyped subgroups:integration of the TRITON-TIMI 38 trial data.J Thromb Haemost,2010,8(8):1678-1684.
• [15]Wallentin L,James S,Storey RF,et al.Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes:a genetic substudy of the PLATO trial.Lancet,2010,376(9749):1320-1328.
• [16]Xiong R,Liu W,Chen L,et al.A randomized controlled trial to assess the efficacy and safety of doubling dose clopidogrel versus ticagrelor for the treatment of acute coronary syndrome in patients with CYP2C19*2 homozygotes.Int J Clin Exp Med,2015,8(8):13310-13316.
• [17]Shen DL,Wang B,Bai J,et al.Clinical Value of CYP2C19Genetic Testing for Guiding the Anti-platelet Therapy in a Chinese Population.J Cardiovasc Pharmacol,2016,67(3):232-236.
• [18]Mega JL,Hochholzer W,Frelinger AL,et al.Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.JAMA,2011,306(20):2221-2228.
• [19]Lanning Z.Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention-a systematic review and meta-analysis.Thromb Res,2015,135(3):449-458.
• [20]Kazi DS,Garber AM,Shah RU,et al.Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.Ann Intern Med,2014,160(4):221-232.
• [21]Hamm CW,Bassand JP,Agewall S,et al.ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:The Task Force for the management of acute coronary syndromes(ACS)in patients presenting without persistent ST-segment elevation of the European Society of Cardiology(ESC).Eur Heart J,2011,32(23):2999-3054.
• [22]Jneid H,Anderson JL,Wright RS,et al.2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction(updating the 2007 guideline and replacing the 2011 focused update):a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol,2012,60(7):645-681.
• [23]宋博凡,高方明.氯吡格雷药物基因组多态性与个体化治疗研究进展.中国介入心脏病学杂志,2015,23(12):697-700.